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INTRODUCTION
Lung cancer is the leading cause of cancer death in most
countries. Although much effort has been made over the last
few decades to improve the survival of lung cancer patients,
overall five-year survival rates remain unsatisfactorily low
(14% in the U.S.A.) (1).
Brain metastasis (BM) is a major cause of the low survival
rate and poor quality of life of cancer patients. The progno-
sis for patients with BM who go untreated is extremely poor
(about one month following diagnosis) (2), whereas patients
with non-small cell lung cancer (NSCLC) who are treated
with radiation therapy survive for about 8 months (3). The
incidence of BM in patients with locally advanced NSCLC
is 12-28% over the entire course of the disease. In most cases
of NSCLC, BM are diagnosed only after the development of
symptoms, which is partly responsible for the poor progno-
sis of patients with NSCLC. In patients with small cell lung
cancer (SCLC), the incidence of detectable BM at the time
of initial diagnosis is 10-14%; the cumulative incidence at
three years for patients that are in complete remission and
that have few signs of disease is 59% (4). For patients with
NSCLC, the incidence of BM at the time of initial diagnosis
is about 6% according to a prospective study in which com-
puterized axial tomography (CT) was used (5). The prognoses
of patients with symptomatic BM are substantially worse than
those in which the metastases are asymptomatic (6-8). Clear-
ly, improvements in systemic and local therapies can improve
the long-term survival of cancer patients, which means that
early and accurate diagnosis of BM has become crucial to im-
proving the quality of life and poor survival rates of cancer
patients.
The use of imaging to detect extrathoracic metastasis, par-
ticularly BM, at the time of initial staging in asymptomatic
patients is the subject of debate (8-10). Imaging is usually
recommended in patients who form part of a population in
which the overall incidence of BM is particularly high, such
as in cases with adenocarcinomas (6, 11-13). Of the different
imaging methods, MRI is more sensitive than CT and is the
method of choice with which to screen for intracranial metas-
tasis (12, 14-17). However, a major drawback to the routine
use of brain MRI is its high cost. Therefore, we carried out the
modified standard MRI or limited MRI procedure to detect
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Screening of Brain Metastasis with Limited Magnetic Resonance 
Imaging (MRI): Clinical Implications of Using Limited Brain MRI 
During Initial Staging for Non-small Cell Lung Cancer Patients 
The purpose of this prospective study was to determine whether using magnetic
resonance imaging (MRI) for early screening for brain metastases (BM) can improve
quality of life, survival in patients with non-small cell lung cancer (NSCLC). The
study group comprised 183 patients newly diagnosed with NSCLC. All patients
underwent limited brain MRI and routine workups. The control group comprised
131 patients with NSCLC who underwent limited brain MRI only if they had neuro-
logic symptoms. The incidence of BM was 20.8% (38/183) in the study group and
4.6% (6/131) in the control group. The rate of upstaging based on the MRI data
was 13.5% (15/111) overall and 15.9% (11/69) in patients that had been consid-
ered initially to be resectable surgically. There was no significant difference in sur-
vival outcome between the groups. Patients who had BM alone had a greater
overall survival time (49 weeks) than those who had multiple systemic metastases
(27 weeks; p=0.0307). In conclusions, limited brain MRI appears to be a useful,
cost-effective method to screen for BM at the time of initial staging. And it may
facilitate timely treatment of patients with NSCLC and improve their survival and
quality of life.
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pilot study limited MRI showed no difference with conven-
tional MRI for detecting BM (sensitivity 97.67%, specifici-
ty 100%) (18). The cost of the modified MRI was US$ 180,
which is substantially lower than the cost of conventional
brain MRI (US$ 480). Based on these results, we conducted
the present study to screen for BM at the time of initial stag-
ing and validated the clinical significance of the early detec-
tion of BM using limited brain MRI. The results have impli-
cations for the quality of life and survival of patients with
NSCLC.
MATERIALS AND METHODS 
Between May, 2001 and April, 2002, 183 patients were
newly diagnosed with primary NSCLC at Chungnam Natio-
nal University Hospital. All patients underwent the following
initial staging procedures: clinical examination; routine blood
tests; chest radiography; chest CT (including liver and adrenal
glands); whole-body bone scan; and limited brain MRI. The
limited brain MRI was modified from conventional MRI by
omitting T2-weighted axial, proton density axial, and con-
trast-enhanced T1-weighted images (Table 1) to decrease the
cost from US$ 480 to US$ 180 without any decrease in sen-
sitivity (18). As a control group, we used 131 patients who
were newly diagnosed with NSCLC between May, 2000 and
April, 2001. Control patients underwent the initial staging
procedures described above, except that a brain MRI was car-
ried out only in cases that exhibited neurologic symptoms
related to BM (e.g. headaches, seizures, or unexplained weak-
ness) at the time of initial diagnosis. The incidence of BM
in the initial staging of patients with primary NSCLC and
the incidence of metastases to other systemic sites were com-
pared. We compared the clinically relevant characteristics of
both groups (age, sex, cell type, performance status, clinical
stage, and incidence of brain metastasis). Patients were fol-
lowed up until the 30th of April, 2003 (i.e., a minimum peri-
od of one year) and we analyzed the clinical significance of
early detection of BM and the relationships among the vari-
ous prognostic factors. The statistical analysis was done using
SPSS (version 11.0). Differences between the two groups were
evaluated for statistical significance using a chi-squared test.
Survival data were calculated using the Kaplan-Meier method
and statistical differences were confirmed by means of the
log-rank test. 
RESULTS
There were no statistically significant differences between
the groups with respect to gender, age, performance status,
tumor subtype, or clinical stage (excluding brain metastasis)
(Table 2). 
WI, weighted image; CE, contrast-enhanced.
Image type Conventional Limited
T1-WI axial O O
T2-WI axial  O X
Proton density axial  O X
CE T1-WI axial O O
CE T1-WI coronal O O
CE T1-WI sagittal O X
Cost (US$) 480 180
Table 1. Differences between conventional and limited brain
magnetic resonance imaging (MRI)
Sq, squamous cell carcinoma; Ad, adenocarcinomas; La, large cell car-






Sex (male:female) 139:44 105:26 NS
Median age (yr) (range) 67 (40-79) 66 (31-85) NS
ECOG performance:
0-2 171 123 NS
>3 12 8 NS
Cell type:
Non-squamous 92 70 NS
Ad/La/Un 78/6/8 53/8/9 NS
Sq 91 61 NS
Stage I 13 9 NS
II 13 14 NS
IIIA 32 31 NS
IIIB 38 36 NS
IV 87 (47.6%) 42 (32.1%) <0.05
Brain 38 (20.8%) 6 (4.6%) <0.001
Bone 39 (21.3%) 12 (9.2%) NS
Lung 35 (19.1%) 22 (16.8%) NS
Liver 6 (3.3%) 7 (5.3%) NS
Other 8 (4.4%) 4 (3.1%) NS
Table 2. Patients’ characteristics
Sq, squamous cell carcinoma; Ad, adenocarcinomas; La, large cell car-
cinoma; Un, undifferentiated. *male vs. female: p=0.0124, 
� squamous
vs. nonsquamous: p<0.0001. BM; brain metastasis.
Study group Control group p Value
Overall (initial) 38/183 (20.8%) 6/131 (4.6%) <0.001
Sex:
Male 23/139 (16.5%)* 2/105 (1.9%) <0.001
Female 15/ 44 (34.1%)* 4/ 26 (14.8%) 0.074
Cell type:
Sq 8/91 (8.8%)
� 1/61 (1.6%) 0.067
Non-Sq 30/92 (32.6%)
� 5/70 (7.1%) <0.001
Ad 26/78 (33.3%) 4/53 (7.5%) <0.001
La 2/ 6 (33.3%) 1/ 8 (12.5%) 0.347
Un 2/ 8 (25.0%) 0/ 9 (0.0%) 0.130
Subsequent BM 3 9 -
≤6 mo 1 5 -
>6 mo 2 4 -
Table 3. Incidence of brain metastasis according to the patients’
characteristicsBM was detected in 38 of 183 (20.8%) and 6 of 131 (4.6%)
patients in the study and control groups, respectively (p<
0.001). Twenty-three of 139 (16.5%) males and 15 of 44
(34.1%) females had BM. Patients with non-squamous-type
cells (32.6%) had a higher frequency of BM than those with
squamous-type cells (8.8%). During the follow-up period,
subsequent BM developed in 3 of study group, and 9 of con-
trol group. In these patients, 1 of study group and 5 of con-
trol group had synchronous BM (within 6 months after ini-
tial diagnosis) (Table 3).
Eighteen patients (47.4%) had a single focus of metastasis
within the brain, 17 patients (44.7%) had multiple intracra-
nial foci, and 3 patients (7.9%) had a leptomeningeal pat-
tern of metastasis (Table 4). Only 7 of 38 patients (18.4%)
in which BM was observed using limited MRI also exhibit-
ed clinical symptoms related to BM (Table 4). In 15 of 38
patients (39.5%) in which BM was observed using limited
MRI, the brain was the only site of systemic metastasis, and
these 15 patients were upstaged to stage IV based solely on
the diagnosis of BM. This number included 11 of 68 patients
(15.9%) that were considered initially to be resectable sur-
gically in the absence of BM. Two stage I, three stage II, six
stage IIIA, and four stage IIIB patients were upstaged to stage
IV (Table 5).
For the survival analysis, 10 of 183 patients in the study
group were excluded due to insufficient follow-up data. The
survival analysis was carried out on 173 patients. The overall
median survival time and one-year survival rate of patients
with BM were 43 weeks and 39.5% and 31 weeks and 16.7%
for the study and control groups, respectively. The number
of patients in the control group was too small to determine
whether there were any statistically significant differences
between the two groups. The one-year survival rate and medi-
an survival time of patients who had BM (46.7% and 49
weeks, respectively) was greater only than patients who had
multiple systemic metastases that included the brain (34.8%
and 27 weeks, respectively). Eighteen patients had between
one and three metastatic nodules in the brain that could be
accessed for stereotactic radiosurgery and 20 patients (includ-
ing three with leptomeningeal involvement) had multiple
(>3 nodules) foci within the brain. The one-year survival rate
and median survival time for the former and latter type of
patient was 44.4% and 45 weeks and 35.0% and 24 weeks,
respectively. Of the 38 patients who had BM and were strong-
ly recommended to receive radiation therapy to the brain with
systemic chemotherapy, 14 were treated with whole brain
irradiation only and 23 were treated with both radiation and
chemotherapy. One patient refused any further treatment.
The one-year survival rate and median survival time of irra-
diation-treated patients was 21.4% and 21 weeks, respec-
tively, and the one-year survival rate and median survival time
of those treated with both radiation and chemotherapy was
52.2% and 49 weeks, respectively. The one-year survival rate
and median survival time for symptomatic vs. asymptomatic
patients was 42.9% and 45 weeks and 38.7% and 43 weeks,
respectively (Table 6).





Number of metastatic foci:
1-3 18 (47.4%) 2 (33.3%)
Multiple (>3) 17 (44.7%) 4 (66.6%)
Leptomeningeal 3 (7.9%)
Metastasis site:
Brain only 15 (39.5%) 2 (33.3%)
Brain plus other systemic sites 23 (60.5%) 4 (66.7%)
Symptoms related to brain metastasis:
Symptomatic 7 (18.4%) 6 (100%)
Asymptomatic 31 (81.6%) -






Study group 43 39.5% (15/38)
Control group 31 (p=0.44) 16.7% (1/6) 
(p=0.2804)
Systemic metastasis or not:
Brain metastasis only 49 46.7% (7/15)
Systemic metastasis 27 (p=0.0307) 34.8% (8/23) 
(p=0.4638)
Number of metastatic foci in brain:
1-3 45 44.4%  (8/18)
Multiple (>3)  24 (p=0.0835) 35.5% (7/20) 
(p=0.6456)
Symptoms related to brain metastasis:
Symptomatic 45 42.9% (3/7)
Asymptomatic 43 (p=0.5660) 38.7% (12/31) 
(p=0.3689)
Treatment modality:*
Radiation only 21 21.4% (3/14)
Radiation plus chemotherapy 49 (p=0.0196) 52.2% (12/23) 
(p=0.0647)
*No treatment: 1 case.
Table 6. Median survival period and one-year survival rate of
patients with brain metastasis detected by limited brain MRI
screening
Before the detection of
brain metastasis
Stage
After the detection of
brain metastasis
I 15 13 (-2)
II 16 13 (-3)
IIIA 38 32 (-6)
IIIB 42 38 (-4)
IV 72 87 (+15)
Overall upstaging rate: 15/111 (13.5%). 
Upstaging rate in patients initially considered resectable surgically: 11/69
(15.9%).
Table 5. Impact of limited brain MRI screening on stage deter-
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The one-year survival rate and median survival time over-
all for stage IV patients were 36.1% and 37 weeks, respective-
ly. The median survival of 12 patients in whom BM was diag-
nosed during the follow-up treatment period was 8 weeks.
DISCUSSION 
Even though locoregional control rates of 50% and higher
have been achieved after neoadjuvant chemoradiotherapy and
definitive resection (multimodal therapy) in patients with
locally advanced NSCLC, the brain is the most frequent site
of initial treatment failure and is the site of approximately one
third of all relapses that occur (11, 13, 19, 20). Therefore,
treatment strategies that reduce the risk of BM are needed
to optimize the efficacy of multimodal therapy and to improve
survival.
Between 25 and 30% of all patients with lung cancer devel-
op BM at some stage, and this incidence is likely to increase
if survival is prolonged by means of aggressive multi-modal
treatment. The increasing frequency of treatment failure, the
development of new imaging techniques and treatments, as
well as the reports of prolonged survival of patients that have
received aggressive treatment, suggest that approaches to treat-
ing patients who have BM should be reassessed. Specifically,
novel treatment paradigms should be developed to ensure
that such patients receive optimal therapeutic intervention. To
this end, prophylactic cranial irradiation in NSCLC and SCLC
patients has been introduced and has led to several reports
of positive outcomes, although a large-scale study is needed
to confirm this (11, 13, 21). An alternative means to the same
end is the introduction of brain imaging when the initial
workup is carried out. This approach would facilitate the early
detection of BM and promote the timely application of appro-
priate treatments, which would improve the survival rates
of cancer patients. However, such early imaging should be
considered only if it is practicable and available at a reason-
able cost. Considering each of the aforementioned factors, we
designed the present study to assess the clinical effectiveness
of using limited brain imaging at the time of initial screen-
ing of lung cancer patients.
The rate of BM in patients with locally advanced NSCLC
has been estimated previously to be between 17 and 32%
(median: 22%) with a median time-to-brain recurrence of
7.5-9.3 months (8, 11, 13). It has been shown previously that
most recurrences of metastases within the central nervous sys-
tem occur within 2 yr of the initial diagnosis (13). Further-
more, BM is a direct cause of death in between one third and
one half of affected patients (12).
The incidence of BM in the initial screening of patients
with primary lung cancer has been reported to be between
12 and 18% (22, 23). In the present study, the incidence was
18.9%. We suspect that this slightly higher incidence was
the result of using the limited brain MRI procedure, which
is more sensitive than brain CT (5, 17). There are several risk
factors that are related to BM, including non-squamous his-
tological characteristics (particularly adenocarcinomas), bulky
lymph nodes in the mediastinum, younger age, stage IIIB,
etc. (5, 6, 11-13, 24, 25). Our data supported the same trend
and, in addition, suggested that the incidence of such risk
factors is greater in females than in males. Specifically, in the
present study, the incidence of BM and non-squamous tumors
in females was 30.6 and 26.2%, respectively, which was sta-
tistically higher than in males (15.5 and 8.8%, respectively).
The incidence of BM in all patients with adenocarcinomas
was 33.3%, whereas the incidence in females with adenocar-
cinomas was 50%. In clinical stage IV patients, the brain was
the second most common site of metastasis (38/87 patients
or 43.7%), following bone (39/87, 44.8%), and was a more
common site of metastasis than lung, liver, and the adrenal
glands.
Most patients with BM were asymptomatic, even those
with multiple foci. Symptomatic metastasis was observed in
only 7 of 38 patients (18.4%). Although neurological symp-
toms have been reported to be associated with a poor prog-
nosis (7, 8, 14), the survival rates in the present study were
unrelated to the presence of clinical symptoms. We found
that patients who had a single focus of BM, and isolated BM,
and who were treated with chemotherapy had better survival,
as reported by others. The survival rate of patients who had
BM was equivalent to those who did not have any clinical
symptoms of BM; this was due to early treatment using whole
brain radiotherapy, stereotactic radiosurgery, and chemother-
apy. Fujita et al. reported that the use of chemotherapy to con-
trol not only BM but also extracranial lesions prolonged the
survival of patients with BM due to NSCLC (26). In the pre-
sent study, the survival rates of patients who had BM and who
received both chemotherapy and radiotherapy were similar to
those of patients in stage IIIB (data not shown), which would
appear to support our hypothesis that early detection of BM
and subsequent application of appropriate treatment may
improve overall survival.
In the present study, 15 patients (15/111, 13.5%) were
upstaged from clinical stage I (n=2), II (n=3), IIIA (n=6), or
IIIB (n=4) to stage IV, because of the presence of BM, includ-
ing 11 patients (11/68, 15.9%) who had been considered
initially to be suitable for surgical resection in the absence of
evidence for the presence of BM. All of the aforementioned
patients were treated with either radiotherapy alone (n=7)
or both radiotherapy and chemotherapy (n=8). The median
survival time and one-year survival rate of the former and
latter patients was 43 weeks and 28.6% and 72 weeks and
66.7%, respectively. That was greater than the survival rate
of all patients with BM (median survival time and one-year
survival rate for radiotherapy only and radiotherapy plus che-
motherapy for all patients with BM were 21 weeks and 21.4%,
and 49 weeks and 52.2%, respectively) (Table 6). During a
follow up period of at least one year, 12 patients (3 of studyLimited Brain MRI in Staging NSCLC 125
group and 5 of control group) subsequently developed BM.
All of these patients (except one) were treated with chemo-
therapy after the diagnosis of BM. Initially, these patients
responded to chemotherapy such that four exhibited partial
responses, five exhibited a stable disease state, and three exhib-
ited progression of the disease. The median time to relapse
in treated patients (n=11) was 38 weeks, which is similar to
the time reported by Ceresoli et al. (9 months) (13). These 11
patients were treated with radiation only without any further
chemotherapy; their median survival time after the diagno-
sis of BM was 8 weeks, which was shorter than that of patients
in whom metastasis was detected during the initial screen-
ing and who were treated with radiation therapy alone (21
weeks). Their overall median survival time and one-year sur-
vival rate (after the diagnosis of lung cancer) was 38 weeks
and 27.3%, respectively, worse than the study group that
had BM at the time of the initial screening (43 weeks and
39.5%) and worse than patients who received whole-brain
radiation and chemotherapy (49 weeks and 52.2%) following
the initial screening. Nevertheless, these outcomes were slight-
ly better than those of the control patients, who were diag-
nosed and treated for brain metastasis only upon the devel-
opment of symptoms (31 weeks and 16.7%).
In conclusion, limited brain MRI appears to be a useful
and cost-effective means by which to detect BM at the time
of initial staging of lung cancer patients. Such early detec-
tion of BM enabled patients to be treated immediately with
radiotherapy and chemotherapy and led to improved rates of
survival. Consequently, we recommend that limited brain
MRI should be used as an initial screening procedure for the
early detection of BM. This will allow lung cancer patients to
receive the appropriate treatment in a timely manner, which
should improve both the survival and quality of life of such
patients.
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